

# Comprehensive genetic assessment of the *ESR1* locus identifies a risk region for endometrial cancer

Tracy A O'Mara<sup>1</sup>, Dylan M Glubb<sup>1</sup>, Jodie N Painter<sup>1</sup>, Timothy Cheng<sup>2</sup>, Joe Dennis<sup>3</sup>, The Australian National Endometrial Cancer Study Group (ANECs)<sup>1</sup>, John Attia<sup>4,5</sup>, Elizabeth G Holliday<sup>4,5</sup>, Mark McEvoy<sup>5</sup>, Rodney J Scott<sup>4,6,7,8</sup>, Katie Ashton<sup>4,7,8</sup>, Tony Proietto<sup>9</sup>, Geoffrey Otton<sup>9</sup>, Mitul Shah<sup>10</sup>, Shahana Ahmed<sup>10</sup>, Catherine S Healey<sup>10</sup>, Maggie Gorman<sup>2</sup>, Lynn Martin<sup>2</sup>, National Study of Endometrial Cancer Genetics Group (NSECG)<sup>2</sup>, Shirley Hodgson<sup>11</sup>, Peter A Fasching<sup>12,13</sup>, Alexander Hein<sup>13</sup>, Matthias W Beckmann<sup>13</sup>, Arif B Ekici<sup>14</sup>, Per Hall<sup>15</sup>, Kamila Czene<sup>15</sup>, Hatef Darabi<sup>15</sup>, Jingmei Li<sup>15</sup>, Matthias Dürst<sup>16</sup>, Ingo Runnebaum<sup>16</sup>, Peter Hillemanns<sup>17</sup>, Thilo Dörk<sup>18</sup>, Diether Lambrechts<sup>19,20</sup>, Jeroen Depreeuw<sup>19,20,21</sup>, Daniela Annibali<sup>21</sup>, Frederic Amant<sup>21</sup>, Hui Zhao<sup>19,20</sup>, Ellen L Goode<sup>22</sup>, Sean C Dowdy<sup>23</sup>, Brooke L Fridley<sup>24</sup>, Stacey J Winham<sup>22</sup>, Helga B Salvesen<sup>25,26</sup>, Tormund S Njølstad<sup>25,26</sup>, Jone Trovik<sup>25,26</sup>, Henrica M J Werner<sup>25,26</sup>, Emma Tham<sup>27</sup>, Tao Liu<sup>27</sup>, Miriam Mints<sup>28</sup>, RENDOCAS<sup>27,28</sup>, Manjeet K Bolla<sup>3</sup>, Kyriaki Michailidou<sup>3</sup>, Jonathan P Tyrer<sup>10</sup>, Qin Wang<sup>3</sup>, John L Hopper<sup>29</sup>, AOCs Group<sup>1,30</sup>, Julian Peto<sup>31</sup>, Anthony J Swerdlow<sup>32,33</sup>, Barbara Burwinkel<sup>34,35</sup>, Hermann Brenner<sup>36,37,38</sup>, Alfons Meindl<sup>39</sup>, Hiltrud Brauch<sup>38,40,41</sup>, Annika Lindblom<sup>27</sup>, Jenny Chang-Claude<sup>35</sup>, Fergus J Couch<sup>22,42</sup>, Graham G Giles<sup>29,43,44</sup>, Vessela N Kristensen<sup>45,46,47</sup>, Angela Cox<sup>48</sup>, Paul D P Pharoah<sup>10</sup>, Alison M Dunning<sup>10</sup>, Ian Tomlinson<sup>2</sup>, Douglas F Easton<sup>3,10</sup>, Deborah J Thompson<sup>3</sup> and Amanda B Spurdle<sup>1</sup>

<sup>1</sup>Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, Queensland 4006, Australia

<sup>2</sup>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK

<sup>3</sup>Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK

<sup>4</sup>Hunter Medical Research Institute, John Hunter Hospital, Newcastle, New South Wales 2305, Australia

<sup>5</sup>School of Medicine and Public Health, Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, New South Wales 2305, Australia

<sup>6</sup>Hunter Area Pathology Service, John Hunter Hospital, Newcastle, New South Wales 2305, Australia

<sup>7</sup>Centre for Information Based Medicine, <sup>8</sup>School of Biomedical Sciences and Pharmacy, and <sup>9</sup>School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales 2308, Australia

<sup>10</sup>Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK

<sup>11</sup>Department of Clinical Genetics, St George's, University of London, London SW17 0RE, UK

<sup>12</sup>Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA

<sup>13</sup>Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen 91054, Germany

<sup>14</sup>Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen 91054, Germany

<sup>15</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm SE-171 77, Sweden

<sup>16</sup>Department of Gynaecology, Jena University Hospital – Friedrich Schiller University, Jena 07743, Germany

<sup>17</sup>Hannover Medical School, Clinics of Gynaecology and Obstetrics, Hannover 30625, Germany

<sup>18</sup>Gynaecology Research Unit, Hannover Medical School, Hannover 30625, Germany

<sup>19</sup>Vesalius Research Center, Leuven 3000, Belgium

<sup>20</sup>Laboratory for Translational Genetics, Department of Oncology, University Hospitals Leuven, Leuven 3000, Belgium

- <sup>21</sup>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Hospitals, KU Leuven – University of Leuven, 3000, Belgium
- <sup>22</sup>Department of Health Sciences Research, and <sup>23</sup>Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA
- <sup>24</sup>Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
- <sup>25</sup>Department of Clinical Science, Centre for Cancerbiomarkers, The University of Bergen 5020, Norway
- <sup>26</sup>Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen 5021, Norway
- <sup>27</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm SE-171 77, Sweden
- <sup>28</sup>Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm SE-171 77, Sweden
- <sup>29</sup>Melbourne School of Population and Global Health, Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, Victoria 3010, Australia
- <sup>30</sup>Peter MacCallum Cancer Center, The University of Melbourne, Melbourne 3002, Australia
- <sup>31</sup>London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
- <sup>32</sup>Division of Genetics and Epidemiology, Institute of Cancer Research, London SM2 5NG, UK
- <sup>33</sup>Division of Breast Cancer Research, Institute of Cancer Research, London SM2 5NG, UK
- <sup>34</sup>Department of Gynecology and Obstetrics, Molecular Biology of Breast Cancer, University of Heidelberg, Heidelberg 69120, Germany
- <sup>35</sup>Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg 69120, Germany
- <sup>36</sup>Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
- <sup>37</sup>Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
- <sup>38</sup>German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg 69120, Germany
- <sup>39</sup>Division of Tumor Genetics, Department of Obstetrics and Gynecology, Technical University of Munich, Munich 0333, Germany
- <sup>40</sup>Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart 70376, Germany
- <sup>41</sup>University of Tübingen, Tübingen 72074, Germany
- <sup>42</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
- <sup>43</sup>Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria 3004, Australia
- <sup>44</sup>Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia
- <sup>45</sup>Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo 0310, Norway
- <sup>46</sup>The KG Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo 0316, Norway
- <sup>47</sup>Department of Clinical Molecular Oncology, Division of Medicine, Akershus University Hospital, Lørenskog 1478, Norway
- <sup>48</sup>Sheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield S10 2RX, UK

Correspondence should be addressed to A B Spurdle  
**Email**  
 Amanda.Spurdle@qimrberghofer.edu.au

## Abstract

Excessive exposure to estrogen is a well-established risk factor for endometrial cancer (EC), particularly for cancers of endometrioid histology. The physiological function of estrogen is primarily mediated by estrogen receptor alpha, encoded by *ESR1*. Consequently, several studies have investigated whether variation at the *ESR1* locus is associated with risk of EC, with conflicting results. We performed comprehensive fine-mapping analyses of 3633 genotyped and imputed single nucleotide polymorphisms (SNPs) in 6607 EC cases and 37 925 controls. There was evidence of an EC risk signal located at a potential alternative promoter of the *ESR1* gene (lead SNP rs79575945,  $P=1.86 \times 10^{-5}$ ), which was stronger for cancers of endometrioid subtype ( $P=3.76 \times 10^{-6}$ ). Bioinformatic analysis suggests that this risk signal is in a functionally important region targeting *ESR1*, and eQTL analysis found that rs79575945 was associated with expression of *SYNE1*, a neighbouring gene. In summary, we have identified a single EC risk signal located at *ESR1*, at study-wide significance. Given SNPs located at this locus have been associated with risk for breast cancer, also a hormonally driven cancer, this study adds weight to the rationale for performing informed candidate fine-scale genetic studies across cancer types.

### Key Words

- ▶ endometrial cancer
- ▶ ESR1
- ▶ single-nucleotide polymorphisms
- ▶ fine-mapping analysis

Endocrine-Related Cancer  
 (2015) 22, 851–861

## Introduction

Endometrial cancer is the most commonly diagnosed gynaecological malignancy in developed countries (<http://globocan.iarc.fr/>). Excessive endogenous and exogenous estrogen exposure or estrogen exposure unopposed by progesterone is a well-established risk factor for the development and progression of endometrial cancer (Kaaks *et al.* 2002, Key & Pike 1988). Estrogen receptor alpha (encoded by *ESR1*) is the predominant receptor responsible for mediating the effects of estrogen in the endometrium.

A number of studies have previously been performed to investigate the hypothesis that variation at the *ESR1* locus may be associated with predisposition to endometrial cancer (Weiderpass *et al.* 2000, Sasaki *et al.* 2002, Iwamoto *et al.* 2003, Einarsdottir *et al.* 2008, 2009, Wedren *et al.* 2008, Ashton *et al.* 2009, 2010, Sliwinski *et al.* 2010, Li *et al.* 2011), but results from these relatively underpowered studies (maximum sample size 713 cases and 1567 controls) have been conflicting. However, comprehensive candidate gene and genome-wide association studies of breast cancer, which shares many risk factors with endometrial cancer, have identified cancer-associated risk variants at the *ESR1* locus (Dunning *et al.* 2009, Zheng *et al.* 2009, Turnbull *et al.* 2010, Hein *et al.* 2012). These findings indicate a need for similar large-scale and comprehensive genetic analysis of endometrial cancer to elucidate the role of *ESR1* variants in the risk of endometrial cancer.

Here we present the results from fine-mapping of the *ESR1* locus by dense SNP genotyping and imputation in 6607 endometrial cancer cases and 37 925 controls of European descent within the Endometrial Cancer Association Consortium.

## Materials and methods

### Datasets

Genotyping of the fine-mapping dataset was performed on a custom Illumina Infinium iSelect array ('iCOGS'; designed by the Collaborative Oncological Gene-environment Study, details summarized in Bahcall (2013)). All studies have the relevant IRB approval in each country in accordance with the principles embodied in the Declaration of Helsinki, and informed consent was obtained from all participants. Details of iCOGS genotyping of endometrial cancer cases and control samples can be found in Supplementary Table 1, see section on supplementary data given at the end of this article and in Painter *et al.* (2014).

All cases and controls selected for analysis were of European ancestry, as defined by Identity-By-State (IBS) scores between study individuals and individuals in HapMap (<http://hapmap.ncbi.nlm.nih.gov/>). The final analysis of the iCOGS dataset included genotypes for 4401 women with a confirmed diagnosis of endometrial cancer and 28 758 healthy female controls genotyped by the Breast Cancer Association Consortium (BCAC) or the Ovarian Cancer Association Consortium (OCAC). Additionally, three Caucasian GWAS datasets (ANECS, SEARCH and NSECG) were as previously described, totalling 2206 cases and 9167 controls after quality control (Spurdle *et al.* 2011, Painter *et al.* 2014). Overall, there were 6607 endometrial cancer cases and 37 925 controls included in the meta-analysis of the four datasets (ANECS, SEARCH and NSECG GWAS datasets and the iCOGS dataset).

### Fine-mapping

The study herein includes SNPs in a 1 Mb region including *ESR1* (chr6: 151 600 000–152 650 000; NCBI build 37 assembly). SNPs with a minor allele frequency >2% using the 1000 Genomes Project (March 2010 Pilot version 60 CEU project data) were considered for inclusion for *ESR1* fine-mapping on the iCOGS array by BCAC. In total, 975 SNPs were selected, comprising 277 SNPs correlated ( $r^2 > 0.1$ ) with three previously reported breast cancer associated SNPs (rs2046210, rs3757318 and rs3020314), and a 698 SNP set tagging all remaining SNPs in the region with  $r^2 > 0.9$ .

### Regional imputation

Genotypes for SNPs present in 1000 Genomes Phase 1 (April 2012 release) were imputed for the fine-mapping dataset and each GWAS dataset using IMPUTE V2.0 (Howie *et al.* 2009). Imputation was performed separately for each dataset. SNPs with an imputation information score >0.8 for all four datasets and minor allele frequency >0.01 were included in analysis. Following quality control, a total of 3633 genotyped and imputed SNPs were available across all four datasets (the three GWAS and iCOGS datasets).

### Association analysis

Odds ratios for each SNP were estimated for the four imputed datasets separately, using unconditional logistic

regression with a per-allele (one degree-of-freedom) model, based on the expected genotyped dosages for the imputed SNPs. The GWAS datasets were each analysed as a single stratum, with adjustment for the first two (ANECS and NSECG) and three (SEARCH) principal components. For the iCOGS dataset, analyses were performed adjusting for strata and for the first ten principal components, as previously described (Painter *et al.* 2014). The numbers of principal components included in the analyses were selected to adequately account for population stratification in each of the datasets. Results from the four studies were combined using standard fixed-effects meta-analysis, and between-study heterogeneity assessed by Q statistic (Higgins & Thompson 2002). Risk estimation was performed separately for each tested phenotype (endometrial cancer, endometrioid endometrial cancer, non-endometrioid endometrial cancer). To determine independently associated SNPs, we used forward stepwise logistic regression based on all SNPs with  $P < 0.05$  in the single-SNP analysis. At each stage, SNPs were included in the model if they were significant at  $P < 0.05$  after adjustment for other SNPs. To assess possible interaction with BMI group ( $\leq 30 \text{ kg/m}^2$  or  $> 30 \text{ kg/m}^2$ ) for lead SNP rs79575945, the significance of multiplicative interaction was assessed by the change in the likelihood ratio estimate after inclusion of a BMI-by-genotype interaction term to a simpler model without this term. Analyses were conducted using R, including the GenABEL (Aulchenko *et al.* 2007), meta packages (Schwarzer 2010) and SNPTESTv2 (Ferreira & Marchini 2011). All statistical tests were two-sided.

### eQTL analysis

Data from endometrial tumours were accessed from The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Research Network *et al.* 2013). Germline SNP genotypes (Affymetrix 6.0 arrays) were downloaded through the controlled access portal, while epidemiological data, normalized RNA-Seq data and copy-number information were downloaded through the public access TCGA portal. There were 290 TCGA patients (221 endometrioid histology) with complete genotype, RNA-Seq and copy-number data included in the analysis. Quality control was performed on the germline SNP genotypes as previously described (Carvajal-Carmona *et al.* 2015). To increase the number of SNPs in the analysis, we imputed genotypes for SNPs present in the 1000 Genomes dataset v3 in the *ESR1* region (chr6: 150 125 000–152 650 000, April 2012 release) which were not genotyped by the Affymetrix 6.0 platform

using minimac (Howie *et al.* 2012, Fuchsberger *et al.* 2015) Software. Haplotypes were phased using the MaCH program (Li *et al.* 2009, 2010) before running minimac for genotype imputation, using the recommended parameters (20 iterations of the Markov sampler and 200 states). SNPs imputed with a RSQR (quality measure)  $> 0.8$  and minor allele frequency  $> 0.01$  were included in the eQTL analysis. RNA-Seq expression for genes 500 kb upstream and downstream of *ESR1* (*SYNE1*, *ESR1*, *CCDC170*, *C6orf211*, *RMND1*, *ZBTB2*, *AKAP12*, *MYCT1*) were adjusted for somatic copy number variation, as previously described by Li *et al.* (2013). The associations between genotype and adjusted expression for each gene were evaluated using linear regression models by the mach2qtl program (Li *et al.* 2009, 2010). Associations were considered to be statistically significant after correction for the total number of genes analysed across the region ( $0.05/8 \text{ genes} = 6.25 \times 10^{-3}$ ).


### Results

Meta-analysis performed on 3633 SNPs that passed quality control criteria in the four studies (iCOGS, ANECS, SEARCH and NSECG) identified 401 SNPs associated with endometrial cancer risk with  $P < 0.05$  (Supplementary Table 2, see section on supplementary data given at the end of this article), compared to 182 expected by chance. When analysis was restricted to endometrioid-only endometrial cancer, 411 mostly overlapping SNPs were identified to be associated with a  $P < 0.05$  (Supplementary Table 2).

Imputed SNP rs79575945 displayed the strongest association for endometrial cancer risk (per A-allele OR 0.85 and 95% CI 0.79–0.92,  $P = 1.85 \times 10^{-5}$ ; Fig. 1). The risk association was slightly stronger for endometrioid endometrial cancer (per A-allele OR 0.83 and 95% CI 0.77–0.90,  $P = 3.76 \times 10^{-6}$ ; 5611 endometrioid cases and 37 926 controls). No other SNPs reached significance ( $P < 1.85 \times 10^{-5}$ ) after conditioning on rs79575945, suggesting the presence of a single endometrial risk signal at this locus. Similar associations were observed for rs9341019 in the same linkage disequilibrium (LD) block as rs79575945, which was genotyped in all four datasets (rs9341019 OR 0.84 and 95% CI 0.76–0.92,  $P = 2.2 \times 10^{-4}$ ;  $r^2 = 0.27$  to rs79575945).

Supplementary Table 3, see section on supplementary data given at the end of this article lists the 47 SNPs most likely to be the causal variant underlying the risk associations with most significant 'lead' SNPs rs79575945. This SNP set was defined as the SNPs which were in LD ( $r^2 > 0.2$ ) and had a likelihood of association





**Figure 1**

Forest plot of odds ratios for the GWAS and iCOGS fine-mapping datasets for SNP rs79575945 for all histologies and for endometrioid histology.

with endometrial cancer <100:1 with the relevant lead SNP (Carvajal-Carmona *et al.* 2015, Glubb *et al.* 2015).

Given BMI is a major epidemiological risk factor for endometrial cancer, analyses were repeated adjusting for BMI in the subset of cases ( $n=4088$ ) and controls ( $n=16\,590$ ) for whom BMI data were available, and also assessing the possible interaction of rs79575945 with BMI group ( $\leq 30$  kg/m<sup>2</sup> or  $> 30$  kg/m<sup>2</sup>). There was no discernible difference in effect for rs79575945 (unadjusted OR=0.86,  $P=2.4 \times 10^{-3}$ ; adjusted OR=0.82,  $P=3.7 \times 10^{-4}$ ), and no significant evidence of interaction of rs79575945 with BMI ( $P$ -interaction=0.15).

SNP rs79575945 was not significantly associated with risk of non-endometrioid endometrial cancer (OR 0.94 and 95% CI 0.80–1.13,  $P=0.54$ ), although there was reduced power to detect association due to the smaller case sample size (iCOGS fine-mapping and NSECG GWAS datasets only, case  $n=887$ ). No SNP reached study-wide significance for non-endometrioid endometrial cancer risk. Similarly, no significant associations were found in the case-only analysis, comparing endometrioid endometrial cancer patients to non-endometrioid patients (rs79575945 OR 1.08 and 95% CI 0.89–1.30,  $P=0.43$ ).


None of the 47 potentially causal variants (Supplementary Table 3, see section on supplementary data given at the end of this article) showed evidence of an association with *ESR1* expression, using genotype and RNA-Seq data from TCGA. The strongest association observed for any SNP in this region with *ESR1* levels in endometrioid endometrial tumours was rs74575485 located upstream of the rs79575945 risk signal ( $r^2=0.001$ ), but this SNP was not associated with risk

(eQTL  $P=1.45 \times 10^{-3}$ , risk  $P=0.77$ ). We found evidence of an association between the top risk SNP rs79575945 and increased expression of *SYNE1* in endometrioid endometrial tumour (eQTL  $P=3.17 \times 10^{-3}$ ). This association is considered to be statistically significant after correcting for the total number of genes analysed across the region ( $P$  for significance =  $6.25 \times 10^{-3}$ ).

We integrated location of candidate causal SNPs with publicly available genomic data to assess likely functional relevance of SNPs. Candidate causal SNPs mapped to a potential regulatory element, which we defined by evidence of enhancer-specific histone modification (mono-methylation of H3 lysine 4 (H3K4Me1)), DNaseI hypersensitivity sites representative of open chromatin, and regions bound by transcription factors (Fig. 2). Super-enhancers annotated in the study by Hnisz *et al.* (2013) were also found to overlap with candidate causal SNPs (Fig. 2), indicating the functional importance of this region. Importantly, ENCODE data showed presence of DNaseI hypersensitivity sites and evidence for binding of transcription factors in Ishikawa endometrial cancer cells, indicating these regions may be active in endometrial tumours. The binding of these transcription factors were not found to be altered by the candidate causal SNPs, using two independent *in silico* prediction algorithms (Supplementary Table 4, see section on supplementary data given at the end of this article). Candidate causal SNP rs9340770 was predicted to alter binding of p300 by HaploReg, and ENCODE data have shown p300 binding to occur at this region in Ishikawa cells (Encode Project Consortium *et al.* 2012).

## Discussion

We have performed the largest and most comprehensive study assessing the association of SNPs across the *ESR1* gene with endometrial cancer risk. We provide evidence of a study-wide significant association between endometrial cancer risk and imputed SNP rs79575945. Our study implemented parameters to reduce imputation errors and minimize false-positive associations, including rigorous pre-imputation quality control, excluding rare SNPs (minor allele frequency <0.01) and using a high imputation quality score threshold ( $>0.8$ ) for analyses (Marchini & Howie 2010). These measures, and the similar association observed for the best genotyped SNP in the same LD block as imputed lead SNP rs79575945, increase our confidence for the observed association. Given the strong prior evidence for association of this region with a hormonal cancer, as well as with other hormone-related phenotypes (Estrada *et al.* 2012, Perry *et al.* 2014),



**Figure 2**

Association results for all SNPs with endometrial cancer risk from the meta-analysis are shown in the first panel, and association with endometrioid histological subtype the second panel. There was the same number of genotyped or well-imputed samples available for the analysis of each SNP. Only SNPs passing quality control (information score  $> 0.8$  and minor allele frequency  $> 0.01$  across all datasets) are plotted as the negative log of the  $P$  value against relative position across the locus (base position (hg19) displayed across the top). SNPs genotyped in the iCOGS dataset are displayed as diamonds and SNPs imputed are circles. The lead SNP, rs79575945, is shown as a green filled circle and LD with surrounding SNPs indicated by colour (SNPs  $r^2 \geq 0.8$  are red,  $r^2 \geq 0.5$  and  $< 0.8$  are orange,  $r^2 \geq 0.2$  and  $< 0.5$  are yellow and  $r^2 < 0.2$  are unfilled). The SNP most strongly associated with *ESR1* expression in endometrial cancer tumours is shown as a filled blue circle. Red horizontal dashed lines denote study-wide

significance thresholds ( $P = 2 \times 10^{-4}$ ). The third panel shows a schematic of gene structures with exons (vertical boxes) joined by introns (lines). Enhancers predicted in Hnisz *et al.* (2013) which overlap SNPs associated with the three phenotypes are depicted as coloured bars, where the colour matches the schematic of its predicted target gene. Histone modification associated with promoters (H3K4Me1) from seven ENCODE Project cell types are indicated. DNaseI hypersensitivity sites (DHS) and transcription factor (TF) binding identified in 125 and 91 ENCODE Project cell types respectively, are displayed. DNaseI HS and transcription factor binding regions in Ishikawa endometrial cancer cells\* are also shown. The grey vertical stripe indicates the putative promoter region overlapping the risk signal. \*Note in 2015 ENCODE re-identified ECC-1 cells as Ishikawa (<https://www.encodeproject.org/biosamples/ENCBS312UTV/>) (Korch *et al.* 2012).

we considered this a candidate-gene study. The consistency of SNP association with endometrial cancer risk between the four studies gives us confidence in this finding. Using tagger (de Bakker *et al.* 2005), 246 SNPs were calculated to be required to tag our region of interest by pairwise-tagging ( $r^2 \geq 0.5$ ). The most strongly associated SNP had a  $P$  value an order of magnitude smaller than the Bonferroni-adjusted significance threshold based on the number of independent SNPs at the locus ( $P$  for significance =  $0.05/246 = 2.0 \times 10^{-4}$ ). Notably, there was a more significant association for the endometrioid histology subtype which is well-established to be estrogen driven (Kaaks *et al.* 2002).

Neither SNP rs79575945, nor any other in the risk-associated SNP set, has been previously reported to be associated with endometrial cancer risk. Reported associated SNPs from smaller candidate studies investigating the effect of genetic variation at the *ESR1* locus on endometrial cancer risk are not in LD ( $r^2 < 0.2$ ) with rs79575945 and were not validated in our larger study (Table 1).

SNPs associated with multiple phenotypes have been mapped to the *ESR1* locus, notably breast cancer (Zheng *et al.* 2009, Turnbull *et al.* 2010, Hein *et al.* 2012), which shares many risk factors with endometrial cancer, and age-of-menarche (Perry *et al.* 2014) and bone mineral density (Estrada *et al.* 2012), which are both associated with

**Table 1** Associations of ESR1 SNPs previously reported to be associated with endometrial cancer

| SNP<br>Chr:Position<br>(b37) | Effect/<br>reference allele | Frequency<br>of effect<br>allele | Imputation<br>information<br>score | Genotyped/<br>imputed | All cases        |      | Endometrioid Only |      | $r^2$ with<br>rs79575945 | Direction of effect relative to<br>effect allele (reference reporting<br>association with endometrial<br>cancer) <sup>a</sup> |
|------------------------------|-----------------------------|----------------------------------|------------------------------------|-----------------------|------------------|------|-------------------|------|--------------------------|---|
|                              |                             |                                  |                                    |                       | OR (95% CI)      | P    | OR (95% CI)       | P    |                          |   |
| rs2234693<br>6: 152163335    | T/C                         | 0.46                             | 1.00                               | Genotyped             | 0.98 (0.94–1.02) | 0.35 | 0.98 (0.94–1.02)  | 0.32 | 0.12                     | (↓) Ashton et al. (2009)<br>(↓) Einarsdottir et al. (2009)  |
| rs9340799<br>6: 152163381    | A/G                         | 0.35                             | 1.00                               | Genotyped             | 1.04 (1.0–1.08)  | 0.08 | 1.04 (1.00–1.09)  | 0.06 | 0.06                     | (↑) Iwamoto et al. (2003)<br>(↑) Wedren et al. (2008)<br>(↓) Ashton et al. (2009)<br>(↓) Einarsdottir et al. (2009)           |
| rs3853250<br>6: 152159900    | T/G                         | 0.46                             | 0.99                               | Imputed               | 0.98 (0.94–1.02) | 0.35 | 0.98 (0.94–1.02)  | 0.32 | 0.12                     | (↑) Iwamoto et al. (2003)<br>(↑) Wedren et al. (2008)<br>(↓) Einarsdottir et al. (2009)                                       |
| rs1709181<br>6: 152175180    | T/C                         | 0.26                             | 0.98                               | Imputed               | 1.02 (0.98–1.07) | 0.40 | 1.03 (0.99–1.08)  | 0.15 | 0.07                     | (↓) Einarsdottir et al. (2009)  |
| rs4870057<br>6: 152171898    | A/G                         | 0.33                             | 0.91                               | Imputed               | 1.04 (0.99–1.08) | 0.11 | 1.04 (0.99–1.09)  | 0.09 | 0.05                     | (↓) Einarsdottir et al. (2009)  |
| rs2046210<br>6: 151948366    | G/A                         | 0.34                             | 1.00                               | Genotyped             | 1.03 (0.99–1.07) | 0.18 | 1.03 (0.99–1.08)  | 0.17 | 0.0005                   | (↓) Li et al. (2011)  |
| rs2077647<br>6: 152129077    | T/C                         | 0.48                             | 1.00                               | Genotyped             | 0.99 (0.96–1.04) | 0.78 | 1.00 (0.96–1.04)  | 0.85 | 0.11                     | (↑) Sasaki et al. (2002)  |
| rs1801132<br>6: 152265522    | G/C                         | 0.22                             | 0.98                               | Imputed               | 1.03 (0.98–1.08) | 0.27 | 1.01 (0.96–1.07)  | 0.65 | 0.01                     | (↑) Sliwinski et al. (2010)   |

<sup>a</sup>SNPs previously reported as significantly associated with endometrial cancer risk were selected from a literature search. Significance thresholds were stated as  $P < 0.05$  in all publications. Sample sizes for studies were as follows: Ashton, 191 cases and 291 controls; Einarsdottir, 713 cases and 1567 controls; Iwamoto, 92 cases and 65 controls; Li, 953 cases and 947 controls; Sasaki, 113 cases and 200 controls; Sliwinski, 100 cases and 100 controls; Wedren, 702 cases and 1563 controls.

estrogen exposure. However, none of the SNPs reported by these studies are correlated with any of the variants found to be associated with endometrial cancer risk ( $r^2 < 0.2$ ). The lack of overlap between risk variants for endometrial cancer, breast cancer and risk factors associated with estrogen exposure suggest that while these risks could be mediated through the same target gene, they are working via different regulatory mechanisms in different cell types.

Using log-likelihood ratios and LD, we have identified 47 candidate causal variants located at a potential alternative promoter of *ESR1*, represented by lead SNP rs79575945. Bioinformatics data provide evidence that these variants reside within a putative regulatory element for *ESR1* and/or other genes in this region. By cross-referencing the catalogue created using 86 cell lines by Hnisz et al. (2013), we also provide evidence that candidate causal variants lie in a region encompassing super-enhancers that target *ESR1*. Super-enhancers consist of large clusters of transcriptional enhancers and are associated with genes that control and define cell identity (Loven et al. 2013, Whyte et al. 2013). The presence of super-enhancers overlapping the candidate causal variants indicates the functional importance of this region. Four candidate causal variants were predicted to alter transcription factor binding by two independent programs, is-rSNP (Macintyre et al. 2010) and HaploReg (Ward & Kellis 2012). However, none of these transcription factors identified have been examined by ENCODE. There was evidence of binding of transcription factors TAF1, NFIC, TCF12, p300, TEAD4 and FOXM1 overlapping candidate causal SNPs in Ishikawa cells by ENCODE. However, the binding of these transcription factors were not found to be altered by the candidate causal SNPs using is-rSNP and HaploReg. Given transcription factor binding frequently occurs in the absence of a known motif (Kheradpour & Kellis 2014), SNP effects may not have been correctly assessed in this analysis. Functional analysis would therefore be required to assess the impact of these SNPs on transcription factor binding. Using data from HaploReg alone, candidate causal SNP rs9340770 was predicted to alter binding of p300 and ENCODE data indicates that rs9340770 is in a region bound by p300 in Ishikawa cells. SNP rs9340770 is located upstream of an alternative transcript for *ESR1*, and the binding of p300 suggests this could be a putative promoter for these transcripts. Further functional work is required to uncover whether this SNP is affecting the expression of these alternative transcripts by disrupting p300 binding.

Although predicted to be the target gene bioinformatically, eQTL analysis using TCGA data did not find the candidate causal SNPs to be significantly associated with

*ESR1* expression. This is in line with previous fine-mapping studies performed for breast cancer, where candidate causal variants have not been found to act as eQTLs for predicted target genes in breast tissue samples (Ghousaini et al. 2014, Glubb et al. 2015). The reason for this is unclear. It is possible that the effect of candidate SNPs on expression levels cannot always be detected in tumour tissue due to tissue-heterogeneity. Furthermore, eQTLs are context-dependent and might only be expressed in certain stages of cancer development, or only when under particular stimuli.

We did find candidate causal SNPs to be significantly associated with spectrin repeat containing, nuclear envelope 1 (*SYNE1*) expression in endometrioid endometrial cancer tissue. *SYNE1* encodes Nesprin-1 which is reported to be involved in a variety of cellular processes, including Golgi and nucleus organization and cytokinesis (Zhang et al. 2001, Gough et al. 2003, Fan & Beck 2004). Genetic variation in *SYNE1* has been reported to be associated with increased risk of invasive ovarian cancer (Doherty et al. 2010). *SYNE1* is frequently methylated in lung adenocarcinoma and colorectal cancer (Schuebel et al. 2007, Tessema et al. 2008) and mutations in *SYNE1* have been reported in colorectal cancer (Sjoblom et al. 2006). Downregulation of an N-terminal isoform of Nesprin-1, Drop1, has been observed in cancers of the uterus, cervix, kidney, thyroid, pancreas and lung (Marme et al. 2008). Interestingly, a recent study has indicated a role for Nesprin-1 in the DNA damage response pathway, and identified Nesprin-1 as interacting with mismatch repair proteins MSH2 and MSH6 (Sur et al. 2014). Given that mismatch repair deficiency is observed in up to 30% of endometrial tumours (Kanaya et al. 2003), and the eQTL data from our study, the role of *SYNE1* in endometrial cancer should be explored further.

In conclusion, we have identified a single endometrial cancer risk signal, at study-wide significance, located within a potential alternative promoter for *ESR1*. Lead SNP, rs79575945 is also reported to be associated with expression of *SYNE1*, adjacent to *ESR1*. Given SNPs at this locus have previously been identified as predisposing to breast cancer, also a hormonally driven cancer, this study adds weight to the rationale for performing informed candidate fine-scale genetic studies across cancer types (Carvajal-Carmona et al. 2015).

#### Supplementary data

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/ERC-15-0319>.



**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This work was supported by the National Health and Medical Research Council of Australia (ID#1031333 to A B Spurdle, DF, A M Dunning, ID#39435 to ANECS, ID#552402, QIMR Controls); National Health and Medical Research Council of Australia Fellowship Scheme (to A B Spurdle); Principal Research Fellow of Cancer Research UK (to D F Easton); Joseph Mitchell Trust (to A M Dunning); Oxford Comprehensive Biomedical Research Centre (to I Tomlinson); The European Community's Seventh Framework Programme (grant agreement number 22175 (HEALTH-F2-2009-223175) (COGS); Cancer Research UK (C1287/A10118 to COGS and BCAC, C1287/A10710, C12292/A11174, C1281/A12014 to COGS and BCAC, C5047/A15007, C5047/A10692, C8197/A16565, C490/A10124 to SEARCH, CORGI - NSECG, to I Tomlinson); National Institutes of Health (CA128978, R01 CA122443 to MECS and MAY, P30 CA15083 to MECS, P50 CA136393 to MECS and MAY, CAHRES); Post-Cancer GWAS Initiative (1U19 CA148537, 1U19 CA148065, 1U19 CA148112 – the GAME-ON initiative); Department of Defence (W81XWH-10-1-0341); Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer; Komen Foundation for the Cure; The Breast Cancer Research Foundation; Ovarian Cancer Research Fund (to COGS); Cancer Council Queensland (ID#4196615 to ANECS); Council Cancer Tasmania (ID#403031, #ID457636 to ANECS); Medical Research Council (G0000934 to the British 1958 Birth Cohort); Wellcome Trust (068545/Z/02, 085475 to the British 1958 Birth Cohort); Wellcome Trust Human Genetics Grant (090532/Z/09/Z to NSECG); European Union (EU FP7 CHIBCHA to NSECG); The University of Newcastle (to QIMR Controls, to NECS); Gladys M Brawn Senior Research Fellowship (QIMR Controls); The Vincent Fairfax Family Foundation (QIMR Controls); Hunter Medical Research Institute (HCS, NECS); Hunter Area Pathology Service (HCS); ELAN fund of the University of Erlangen (BECS); Verelst Foundation for endometrial cancer (LES); Fred C and Katherine B Anderson Foundation (to MECS, to MAY); Mayo Foundation (to MECS, to MAY); Ovarian Cancer Research Fund with support of the Smith family, in memory of Kathryn Sladek Smith (MECS, PPD/RPCI.07 to OCAC); Helse Vest Grant (MoMaTEC); University of Bergen (MoMaTEC); Melzer Foundation (MoMaTEC); The Norwegian Cancer Society – Harald Andersens legat (MoMaTEC); The Research Council of Norway (MoMaTEC); Haukeland University of Hospital (MoMaTEC); NBN Children's Cancer Research Group (NECS); Ms Jennie Thomas (NECS); regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet (20110222, 20110483, 20110141 and DF 07015 all to RENDOCAS, to KARBAC); The Swedish Labor Market Insurance (100069 to RENDOCAS); The Swedish Cancer Society (11 0439 to RENDOCAS); Agency for Science, Technology and Research of Singapore (CAHRES); Susan G Komen Breast Cancer Foundation (CAHRES); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge (OCAC); Baden-Württemberg state Ministry of Science, Research and Arts (ESTHER); Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (ESTHER); Federal Ministry of Education and Research (BMBF) Germany (01KW9975/5 to GENICA, 01KW9976/8 to GENICA, 01KW9977/0 to GENICA, 01KW0114 to GENICA, to ESTHER); Robert Bosch Foundation (GENICA); Deutsches Krebsforschungszentrum – DKFZ (GENICA); Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum, IPA (GENICA); Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus (GENICA); Deutsche Krebshilfe e.V. (70-2892-BR I to MARIE); Hamburg Cancer Society (MARIE); German Cancer Research Center (MARIE); Breast Cancer Research Foundation (MCBCS); David F. and Margaret T. Grohne Family Foundation (MCBCS); Ting Tsung and Wei Fong Chao Foundation (MCBCS); VicHealth (MCCS); Cancer Council Victoria (MCCS);

Breakthrough Breast Cancer (UKBGS); Institute of Cancer Research (UKBGS); and NHS funding to the NIHR Biomedical Research Centre (UKBGS/ICR).

**Author contribution statement**

A M Dunning, D F Easton, P D P Pharoah, I Tomlinson and A B Spurdle obtained funding for the study. D F Easton and A B Spurdle designed the study and A B Spurdle and T A O'Mara drafted the manuscript. T A O'Mara conducted all statistical analyses. D J Thompson conducted genotype imputation. D M Glubb and T A O'Mara conducted bioinformatics analyses. T A O'Mara and JNP co-ordinated the endometrial cancer iCOGS genotyping, and associated data management. J Dennis, K Michailidou and J P Tyrer co-ordinated quality control and data cleaning for the iCOGS datasets, and K Michailidou provided quality control for the SEARCH GWAS control set. M K Bolla, Q Wang, J P Tyrer and M Shah were responsible for data management. T A O'Mara and A B Spurdle co-ordinated the ANECS GWAS genotyping; A M Dunning co-ordinated the SEARCH GWAS genotyping; I Tomlinson co-ordinated the NSECG GWAS genotyping. T Cheng, J Attia, E G Holliday, M McEvoy, R J Scott, K Ashton, G Otton, T Proietto, S Ahmed, C S Healey, M Gorman, L Martin, S Hodgson, P A Fasching, A Hein, M W Beckmann, A B Keci, P Hall, K Czene, H Darabi, J Li, J Dennis, D Annibaldi, F Amant, E L Goode, S C Dowdy, B L Fridley, S J Winham, H B Salvesen, T S Njølstad, J Trovik, H M J Werner, E Tham, T Liu, M Mints J L Hopper, J Peto, A J Swerdlow, B Burwinkel, H Brenner, A Meindl, H Brauch, A Lindblom, J Chang-Claude, F J Couch, G G Giles, V N Kristensen, A Cox, The Australian National Endometrial Cancer Study Group, National Study of Endometrial Cancer Genetics Group, RENDOCAS and the AOCs Group were involved in the co-ordination and/or extraction of phenotypic information for contributing studies. All authors provided critical review of the manuscript.

**Acknowledgements**

The authors thank the many individuals who participated in this study and the numerous institutions and their staff that supported recruitment, detailed in full in the [Supplementary Text](#), see section on [supplementary data](#) given at the end of this article. Control data was generated by the Wellcome Trust Case Control Consortium (WTCCC), and a full list of the investigators who contributed to the generation of the data is available from the WTCCC website. We acknowledge use of DNA from the British 1958 Birth Cohort collection. In addition, the results published here are based partly on data generated by TCGA, established by the NCI and the National Human Genome Research Institute. The authors also thank the specimen donors and relevant research groups associated with this project.

**References**

- Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U & Scott RJ 2009 Estrogen receptor polymorphisms and the risk of endometrial cancer. *BJOG: An International Journal of Obstetrics and Gynaecology* **116** 1053–1061. (doi:10.1111/j.1471-0528.2009.02185.x)
- Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U & Scott RJ 2010 Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. *Cancer Epidemiology* **34** 328–337. (doi:10.1016/j.canep.2010.03.005)
- Aulchenko YS, Ripke S, Isaacs A & van Duijn CM 2007 GenABEL: an R library for genome-wide association analysis. *Bioinformatics* **23** 1294–1296. (doi:10.1093/bioinformatics/btm108)
- Bahcall OG 2013 iCOGS collection provides a collaborative model. Foreword. *Nature Genetics* **45** 343. (doi:10.1038/ng.2592)

- de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ & Altshuler D 2005 Efficiency and power in genetic association studies. *Nature Genetics* **37** 1217–1223. (doi:10.1038/ng1669)
- Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R et al. 2013 Integrated genomic characterization of endometrial carcinoma. *Nature* **497** 67–73. (doi:10.1038/nature12113)
- Carvajal-Carmona LG, O'Mara TA, Painter JN, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS et al. 2015 Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. *Human Genetics* **134** 231–245. (doi:10.1007/s00439-014-1515-4)
- Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ, Wu AH, Pike MC, Ness RB, Moysich K, Chenevix-Trench G et al. 2010 ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. *Cancer Epidemiology, Biomarkers & Prevention* **19** 245–250. (doi:10.1158/1055-9965.EPI-09-0729)
- Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, Vega A, Rodriguez R, Barbosa-Morais NL, Ponder BA, SEARCH et al. 2009 Association of ESR1 gene tagging SNPs with breast cancer risk. *Human Molecular Genetics* **18** 1131–1139. (doi:10.1093/hmg/ddn429)
- Einarsdottir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjolander A, Czene K, Wedren S, Liu ET et al. 2008 ESR1 and EGF genetic variation in relation to breast cancer risk and survival. *Breast Cancer Research* **10** R15. (doi:10.1186/bcr1861)
- Einarsdottir K, Darabi H, Czene K, Li Y, Low YL, Li YQ, Bonnard C, Wedren S, Liu ET, Hall P et al. 2009 Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival. *British Journal of Cancer* **100** 1358–1364. (doi:10.1038/sj.bjc.6604984)
- Encode Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C & Snyder M 2012 An integrated encyclopedia of DNA elements in the human genome. *Nature* **489** 57–74. (doi:10.1038/nature11247)
- Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, Oei L, Albagha OM, Amin N, Kemp JP et al. 2012 Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nature Genetics* **44** 491–501. (doi:10.1038/ng.2249)
- Fan J & Beck KA 2004 A role for the spectrin superfamily member Syne-1 and kinesin II in cytokinesis. *Journal of Cell Science* **117** 619–629. (doi:10.1242/jcs.00892)
- Ferreira T & Marchini J 2011 Modeling interactions with known risk loci—a Bayesian model averaging approach. *Annals of Human Genetics* **75** 1–9. (doi:10.1111/j.1469-1809.2010.00618.x)
- Fuchsberger C, Abecasis GR & Hinds DA 2015 minimac2: faster genotype imputation. *Bioinformatics* **31** 782–784. (doi:10.1093/bioinformatics/btu704)
- Ghousaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM et al. 2014 Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature Communications* **4** 4999. (doi:10.1038/ncomms5999)
- Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, Carlebur S, O'Reilly M, Betts JA, Hillman KM et al. 2015 Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *American Journal of Human Genetics* **96** 5–20. (doi:10.1016/j.ajhg.2014.11.009)
- Gough LL, Fan J, Chu S, Winnick S & Beck KA 2003 Golgi localization of Syne-1. *Molecular Biology of the Cell* **14** 2410–2424. (doi:10.1091/mbc.E02-07-0446)
- Hein R, Maranian M, Hopper JL, Kapuscinski MK, Southey MC, Park DJ, Schmidt MK, Broeks A, Hogervorst FB, Bueno-de-Mesquita HB et al. 2012 Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE* **7** e42380. (doi:10.1371/journal.pone.0042380)
- Higgins JP & Thompson SG 2002 Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* **21** 1539–1558. (doi:10.1002/sim.1186)
- Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA & Young RA 2013 Super-enhancers in the control of cell identity and disease. *Cell* **155** 934–947. (doi:10.1016/j.cell.2013.09.053)
- Howie BN, Donnelly P & Marchini J 2009 A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genetics* **5** e1000529. (doi:10.1371/journal.pgen.1000529)
- Howie B, Fuchsberger C, Stephens M, Marchini J & Abecasis GR 2012 Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nature Genetics* **44** 955–959. (doi:10.1038/ng.2354)
- Iwamoto I, Fujino T, Douchi T & Nagata Y 2003 Association of estrogen receptor  $\alpha$  and  $\beta$ 3-adrenergic receptor polymorphisms with endometrial cancer. *Obstetrics and Gynecology* **102** 506–511. (doi:10.1016/S0029-7844(03)00578-7)
- Kaaks R, Lukanova A & Kurzer MS 2002 Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. *Cancer Epidemiology, Biomarkers & Prevention* **11** 1531–1543.
- Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M & Inoue M 2003 Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. *Oncogene* **22** 2352–2360. (doi:10.1038/sj.onc.1206365)
- Key TJ & Pike MC 1988 The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. *British Journal of Cancer* **57** 205–212. (doi:10.1038/bjc.1988.44)
- Kheradpour P & Kellis M 2014 Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments. *Nucleic Acids Research* **42** 2976–2987. (doi:10.1093/nar/gkt1249)
- Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC & Bradford AP 2012 DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. *Gynecologic Oncology* **127** 241–248. (doi:10.1016/j.ygyno.2012.06.017)
- Li Y, Willer C, Sanna S & Abecasis G 2009 Genotype imputation. *Annual Review of Genomics and Human Genetics* **10** 387–406. (doi:10.1146/annurev.genom.9.081307.164242)
- Li Y, Willer CJ, Ding J, Scheep P & Abecasis GR 2010 MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genetic Epidemiology* **34** 816–834. (doi:10.1002/gepi.20533)
- Li G, Xiang YB, Courtney R, Cheng JR, Huang B, Long JR, Cai H, Zheng W, Shu XO & Cai Q 2011 Association of a single nucleotide polymorphism at 6q25.1, rs2046210, with endometrial cancer risk among Chinese women. *Chinese Journal of Cancer* **30** 138–143. (doi:10.5732/cjc.010.10516)
- Li Q, Seo JH, Stranger B, McKenna A, Pe'er I, Laframboise T, Brown M, Tyekucheva S & Freedman ML 2013 Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. *Cell* **152** 633–641. (doi:10.1016/j.cell.2012.12.034)
- Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI & Young RA 2013 Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* **153** 320–334. (doi:10.1016/j.cell.2013.03.036)
- Macintyre G, Bailey J, Haviv I & Kowalczyk A 2010 is-rSNP: a novel technique for in silico regulatory SNP detection. *Bioinformatics* **26** i524–i530. (doi:10.1093/bioinformatics/btq378)
- Marchini J & Howie B 2010 Genotype imputation for genome-wide association studies. *Nature Reviews. Genetics* **11** 499–511. (doi:10.1038/nrg2796)
- Marme A, Zimmermann HP, Moldenhauer G, Schorpp-Kistner M, Muller C, Keberlein O, Giersch A, Kretschmer J, Seib B, Spiess E et al. 2008 Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas. *International Journal of Cancer* **123** 2048–2056. (doi:10.1002/ijc.23763)
- Painter JN, O'Mara TA, Batra J, Cheng T, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K et al. 2014 Fine-mapping of the HNF1B

- multicancer locus identifies candidate variants that mediate endometrial cancer risk. *Human Molecular Genetics* **24** 1478–1492. (doi:10.1093/hmg/ddu552)
- Perry JR, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, He C, Chasman DI, Esko T, Thorleifsson G et al. 2014 Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature* **514** 92–97. (doi:10.1038/nature13545)
- Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N & Dahiya R 2002 Polymorphisms of estrogen receptor  $\alpha$  gene in endometrial cancer. *Biochemical and Biophysical Research Communications* **297** 558–564. (doi:10.1016/S0006-291X(02)02248-9)
- Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S et al. 2007 Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. *PLoS Genetics* **3** 1709–1723. (doi:10.1371/journal.pgen.0030157)
- Schwarzer G 2010 Meta: Meta-Analysis with R, package 1.6-1. (available at: <http://CRAN.R-project.org/package=meta>)
- Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N et al. 2006 The consensus coding sequences of human breast and colorectal cancers. *Science* **314** 268–274. (doi:10.1126/science.1133427)
- Sliwinski T, Sitarek P, Stetkiewicz T, Sobczuk A & Blasiak J 2010 Polymorphism of the ER $\alpha$  and CYP1B1 genes in endometrial cancer in a Polish subpopulation. *Journal of Obstetrics and Gynaecology* **36** 311–317. (doi:10.1111/j.1447-0756.2009.01143.x)
- Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O'Mara T, Walker LC, Montgomery SB, Dermitzakis ET, Australian National Endometrial Cancer Study Group et al. 2011 Genome-wide association study identifies a common variant associated with risk of endometrial cancer. *Nature Genetics* **43** 451–454. (doi:10.1038/ng.812)
- Sur I, Neumann S & Noegel AA 2014 Nesprin-1 role in DNA damage response. *Nucleus* **5** 173–191. (doi:10.4161/nucl.29023)
- Tessema M, Willink R, Do K, Yu YY, Yu W, Machida EO, Brock M, Van Neste L, Stidley CA, Baylin SB et al. 2008 Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. *Cancer Research* **68** 1707–1714. (doi:10.1158/0008-5472.CAN-07-6325)
- Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghousaini M, Hines S, Healey CS et al. 2010 Genome-wide association study identifies five new breast cancer susceptibility loci. *Nature Genetics* **42** 504–507. (doi:10.1038/ng.586)
- Ward LD & Kellis M 2012 HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Research* **40** D930–D934. (doi:10.1093/nar/gkr917)
- Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F et al. 2008 Estrogen receptor  $\alpha$  gene polymorphism and endometrial cancer risk – a case-control study. *BMC Cancer* **8** 322. (doi:10.1186/1471-2407-8-322)
- Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A & Baron JA 2000 Estrogen receptor  $\alpha$  gene polymorphisms and endometrial cancer risk. *Carcinogenesis* **21** 623–627. (doi:10.1093/carcin/21.4.623)
- Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI & Young RA 2013 Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* **153** 307–319. (doi:10.1016/j.cell.2013.03.035)
- Zhang Q, Skepper JN, Yang F, Davies JD, Hegyi L, Roberts RG, Weissberg PL, Ellis JA & Shanahan CM 2001 Nesprins: a novel family of spectrin-repeat-containing proteins that localize to the nuclear membrane in multiple tissues. *Journal of Cell Science* **114** 4485–4498.
- Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL et al. 2009 Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. *Nature Genetics* **41** 324–328. (doi:10.1038/ng.318)

Received in final form 31 July 2015

Accepted 5 August 2015